First Turn Management LLC Invests $27.75 Million in Guardant Health, Inc. $GH

First Turn Management LLC purchased a new position in Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 271,685 shares of the company’s stock, valued at approximately $27,750,000. Guardant Health accounts for 3.2% of First Turn Management LLC’s portfolio, making the stock its 16th largest holding. First Turn Management LLC owned 0.22% of Guardant Health as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health in the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health in the 4th quarter worth approximately $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health in the 4th quarter worth approximately $35,000. Finally, Parallel Advisors LLC lifted its stake in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $128.62, for a total value of $257,240.00. Following the sale, the chief financial officer directly owned 47,509 shares in the company, valued at $6,110,607.58. The trade was a 4.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the sale, the director owned 11,183 shares in the company, valued at $1,420,017.34. The trade was a 47.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 452,238 shares of company stock worth $51,425,612. Company insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

NASDAQ GH opened at $131.62 on Friday. The company’s 50 day simple moving average is $103.51 and its 200 day simple moving average is $102.14. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $134.28. The company has a market capitalization of $17.45 billion, a P/E ratio of -38.83 and a beta of 1.61.

Analysts Set New Price Targets

GH has been the subject of a number of research analyst reports. Royal Bank Of Canada initiated coverage on shares of Guardant Health in a research note on Thursday. They issued an “outperform” rating and a $185.00 price target for the company. Stifel Nicolaus upped their price target on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target for the company in a research note on Tuesday, June 2nd. Canaccord Genuity Group upped their price target on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $141.95.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.